Posted by Michael Wonder on 22 Jan 2025
Replimune announces biologics license application acceptance and priority review for RP1 for the treatment of advanced melanoma
21 January 2025 - PDUFA action date of 22 July 2025, with priority review.
Replimune Group today announced that the US FDA has accepted the biologics license application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma.
